Tatsuya Ogimoto
Kyoto, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.
Journal: Cancer research
Published: June 26, 2026
A Case of Immunoglobulin A Vasculitis Induced by Ethambutol.
Journal: Internal medicine (Tokyo, Japan)
Published: April 29, 2026
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.
Journal: Cancer research
Published: August 04, 2025
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.
Journal: Molecular and clinical oncology
Published: November 20, 2024
Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
Journal: Cancer science
Published: November 14, 2024
ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.
Journal: JCI insight
Published: September 16, 2024
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
Journal: BMC cancer
Published: July 05, 2024
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Journal: Molecular cancer therapeutics
Published: June 14, 2023
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Journal: Scientific reports
Published: February 07, 2023
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Journal: Oncology letters
Published: May 19, 2022
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Journal: Cancer science
Published: April 27, 2022
Last Updated: 09/26/2026